[
  {
    "ts": null,
    "headline": "Best Dividend Aristocrats For June 2025",
    "summary": "Investors should focus on Aristocrats with strong dividend growth, undervaluation, and high expected returns, but conduct their own due diligence. See more here.",
    "url": "https://finnhub.io/api/news?id=6ee1dcf91ffbd2bdde319f8234879fe63c615bdeedf7461a4dbb0c871beb6455",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748384108,
      "headline": "Best Dividend Aristocrats For June 2025",
      "id": 134736842,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2173105185/image_2173105185.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Investors should focus on Aristocrats with strong dividend growth, undervaluation, and high expected returns, but conduct their own due diligence. See more here.",
      "url": "https://finnhub.io/api/news?id=6ee1dcf91ffbd2bdde319f8234879fe63c615bdeedf7461a4dbb0c871beb6455"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. stock rises Tuesday, still underperforms market",
    "summary": "AbbVie Inc. stock rises Tuesday, still underperforms market",
    "url": "https://finnhub.io/api/news?id=b6d323670accab18a72390b1c15ac7bf9b5534c2dd5c0f235ae5cad73ad4be72",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748363520,
      "headline": "AbbVie Inc. stock rises Tuesday, still underperforms market",
      "id": 134717305,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock rises Tuesday, still underperforms market",
      "url": "https://finnhub.io/api/news?id=b6d323670accab18a72390b1c15ac7bf9b5534c2dd5c0f235ae5cad73ad4be72"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio",
    "summary": "AbbVie (NYSE: ABBV) today announced that key data from its broad oncology portfolio will be showcased across multiple oral presentations and posters at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting (May 30 - June 3, 2025). These new data highlight significant progress in AbbVie's robust oncology pipeline, across a range of difficult-to-treat solid tumors and blood cancers.",
    "url": "https://finnhub.io/api/news?id=2a8855e11cec9903e00b32a1d608bf1bd27cb98a5d3b6d51986580fe5854dbe2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748350800,
      "headline": "AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio",
      "id": 134715929,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) today announced that key data from its broad oncology portfolio will be showcased across multiple oral presentations and posters at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting (May 30 - June 3, 2025). These new data highlight significant progress in AbbVie's robust oncology pipeline, across a range of difficult-to-treat solid tumors and blood cancers.",
      "url": "https://finnhub.io/api/news?id=2a8855e11cec9903e00b32a1d608bf1bd27cb98a5d3b6d51986580fe5854dbe2"
    }
  },
  {
    "ts": null,
    "headline": "John Hancock Disciplined Value Fund Q1 2025 Commentary",
    "summary": "The Russell 1000 Value Indexâthe fundâs benchmarkârecorded a gain of 2.14% in the first quarter. Read more here.",
    "url": "https://finnhub.io/api/news?id=c42fd7704f46c785476f7b80ae46a7782023230483292439ca1d9cd559204576",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748348520,
      "headline": "John Hancock Disciplined Value Fund Q1 2025 Commentary",
      "id": 134709697,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1085514446/image_1085514446.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "The Russell 1000 Value Indexâthe fundâs benchmarkârecorded a gain of 2.14% in the first quarter. Read more here.",
      "url": "https://finnhub.io/api/news?id=c42fd7704f46c785476f7b80ae46a7782023230483292439ca1d9cd559204576"
    }
  },
  {
    "ts": null,
    "headline": "Abbvie Features New Data Across Difficult-To-Treat Solid Tumors and Blood Cancers At Asco 2025",
    "summary": "AbbVie announced that the company features new data from company's novel investigational antibody-drug conjugates including telisotuzumab adizutecan , a next-generation, c-Met directed antibody-drug...",
    "url": "https://finnhub.io/api/news?id=cf3afef6025a265f91b6e45446afbb2bcb09f15d72a257199bdebbda01344b06",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748346643,
      "headline": "Abbvie Features New Data Across Difficult-To-Treat Solid Tumors and Blood Cancers At Asco 2025",
      "id": 134709422,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "AbbVie announced that the company features new data from company's novel investigational antibody-drug conjugates including telisotuzumab adizutecan , a next-generation, c-Met directed antibody-drug...",
      "url": "https://finnhub.io/api/news?id=cf3afef6025a265f91b6e45446afbb2bcb09f15d72a257199bdebbda01344b06"
    }
  },
  {
    "ts": null,
    "headline": "Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1",
    "summary": "Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Myriad Genetics (NASDAQ:MYGN) and its peers.",
    "url": "https://finnhub.io/api/news?id=d67d091c20c3e8e439de4c9954347165c86c40e69e1b5f26019f5a43c3ba4e7d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748316868,
      "headline": "Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1",
      "id": 134715930,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Myriad Genetics (NASDAQ:MYGN) and its peers.",
      "url": "https://finnhub.io/api/news?id=d67d091c20c3e8e439de4c9954347165c86c40e69e1b5f26019f5a43c3ba4e7d"
    }
  }
]